A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial
ConclusionsXP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. XP may be a good option for the treatment of patients after early failure after adjuvant S-1.Trial registrationNCT01412294.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Anemia | Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Xeloda